Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107) (Q83154106)
Jump to navigation
Jump to search
scientific article published on 13 April 2006
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107) |
scientific article published on 13 April 2006 |
Statements
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107) (English)
Nikolas von Bubnoff
Paul W Manley
Jurgen Mestan
Jana Sanger
Christian Peschel
Justus Duyster
13 April 2006